TAP Partner News During ESMO & SITC: Oct/Nov 2023
TAP Partner News During ESMO & SITC: Oct/Nov 2023
Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting
WALTHAM, Mass., October 31, 2023 – Immunitas Therapeutics (“Immunitas”), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced it will present the first proof-of-concept data on its second program, a myeloid and B cell modulating anti CLEC2DToll-like receptor 9 (TLR9) agonist conjugate, at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), held November 1-5.
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
PHILADELPHIA, Oct. 25, 2023 - Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that new pre-clinical data leveraging an mRNA platform to develop in-vivo chimeric antigen receptor macrophage ("CAR-M") will be presented as a late-breaking abstract (#LBA1514) at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting held from Wednesday, November 1, to Sunday, November 5, 2023, in San Diego, California. Two posters highlighting next-generation enhancements to Carisma's CAR-M platform, including a custom intronic shRNA approach and data on Engineered Microenvironment Converters (EM-C), will also be presented.
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting
GAITHERSBURG, Md., Oct. 19, 2023 - NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA , being held November 1-5, 2023.
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
Oct 16, 2023 - Marseilles, France - ImCheck Therapeutics announced today that updated data from its ongoing Phase I/IIa clinical trial EVICTION will be presented at the European Society for Medical Oncology (ESMO) Congress in an oral session on October 22nd in Madrid. The presentation (822O) entitled: “Activation of γ9δ2 T Cells by ICT01 as a Novel Immunotherapeutic Approach for Relapsed/Refractory Hematologic Cancers (EVICTION Study)” will provide safety and patient response results from the Phase I dose escalation portion of the EVICTION trial of ImCheck’s lead antibody, ICT01, administered as a monotherapy to relapsed/refractory patients with hematological cancers, primarily Acute Myeloid Leukemia (AML).
BioInvent to hold two poster presentations at SITC 38th Annual Meeting
Lund, Sweden – September 27, 2023 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it will hold two poster presentations on its anti-tumor necrosis factor receptor 2 (TNFR2) programs at the Society of Immunotherapy for Cancer (SITC) 38th Annual Meeting, held November 3-5, 2023, in San Diego, California. The posters will showcase the latest data from a clinical Phase 1 trial evaluating the first-in-class antibody BI-1808 as single agent, as well as preclinical data for BI-1910. BI-1910 has received an IND approval and is expected to enter clinical development H2 2023.
Affimed Announces Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Mannheim, Germany, September 27, 2023 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract with a comparison of NK cell redirected by the Company’s innate cell engagers (ICE®) versus CAR-NK cells has been accepted for poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 1-5, 2023 in San Diego, California.